Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …
To evaluate the effect of endometriosis medical therapies on bone mineral density (BMD).
Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …
Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …